FSTL3, follistatin like 3, 10272

N. diseases: 33; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.030 Biomarker disease BEFREE We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer. 30388235 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 Biomarker disease BEFREE In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. 30842316 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 Biomarker disease BEFREE In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. 30842316 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer. 30388235 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.030 Biomarker disease BEFREE Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. 28178680 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. 28178680 2017
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 AlteredExpression disease BEFREE FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. 22915069 2012
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 AlteredExpression disease BEFREE FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. 22915069 2012
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 AlteredExpression disease BEFREE Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery. 18617621 2008
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 AlteredExpression disease BEFREE Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery. 18617621 2008
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.030 AlteredExpression disease BEFREE Here, we show that activin-induced growth inhibition is altered in FLRG-expressing breast cancer lines. 17671190 2007
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected. 17671190 2007
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.020 Biomarker disease BEFREE We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2). 31690932 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01). 28178680 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.020 Biomarker disease BEFREE Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content. 23533219 2013
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.020 Biomarker phenotype BEFREE Microarray experiments identified increased expression of certain genes including leptin, soluble vascular endothelial growth factor receptor, human chorionic gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2alpha in the IUGR. 17240240 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE Our data provide strong evidence that endogenous FLRG contributes to tumor cell proliferation through antagonizing endogenous activin effects. 17671190 2007
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.020 AlteredExpression phenotype BEFREE Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta. 16338475 2006
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
0.010 AlteredExpression disease BEFREE In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation. 31690932 2020
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast. 31810141 2020
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.010 Biomarker group BEFREE We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease. 30929550 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.010 AlteredExpression disease BEFREE We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity. 30393997 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.010 GeneticVariation group BEFREE Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs. 30980900 2019